Check for updates

OPEN ACCESS

EDITED AND REVIEWED BY Dieter Steinhilber, Goethe University Frankfurt, Germany

*CORRESPONDENCE Jing Wang, ☑ wangjing@ibms.pumc.edu.cn Huaping Dai, ☑ daihuaping@ccmu.edu.cn Chen Wang, ☑ wangchen@pumc.edu.cn

SPECIALTY SECTION This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology

RECEIVED 27 November 2022 ACCEPTED 12 December 2022 PUBLISHED 18 January 2023

CITATION

Fan M, Xiao H, Song D, Zhu L, Zhang J, Zhang X, Wang J, Dai H and Wang C (2023), Corrigendum: A novel N-arylpyridone compound alleviates the inflammatory and fibrotic reaction of silicosis by inhibiting the ASK1-p38 pathway and regulating macrophage polarization. *Front. Pharmacol.* 13:1109002. doi: 10.3389/fphar.2022.1109002

COPYRIGHT

© 2023 Fan, Xiao, Song, Zhu, Zhang, Zhang, Wang, Dai and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Corrigendum: A novel N-arylpyridone compound alleviates the inflammatory and fibrotic reaction of silicosis by inhibiting the ASK1-p38 pathway and regulating macrophage polarization

Mingming Fan^{1,2}, Huijuan Xiao^{2,3}, Dingyun Song², Lili Zhu², Jie Zhang¹, Xinran Zhang^{2,4}, Jing Wang⁵*, Huaping Dai²* and Chen Wang^{1,2,5}*

¹Department of Respiratory Medicine, The Second Hospital of Jilin University, Jilin, China, ²Department of Pulmonary and Critical Care Medicine Center of Respiratory Medicine, China-Japan Friendship Hospital, Capital Medical University, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ³Department of Pulmonary and Critical Care Medicine, China-Japan Friendship School of Clinical Medicine, Peking University, Beijing, China, ⁴Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China, ⁵State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China

KEYWORDS

silicosis, pulmonary fibrosis, AKEX0011, macrophage polarization, pirfenidone

A Corrigendum on

Corrigendum: A novel N-arylpyridone compound alleviates the inflammatory and fibrotic reaction of silicosis by inhibiting the ASK1-p38 pathway and regulating macrophage polarization

by Fan M, Xiao H, Song D, Zhu L, Zhang J, Zhang X, Wang J, Dai H and Wang C (2022). Front. Pharmacol. 13:848435. doi: 10.3389/fphar.2022.848435

In the original article, there was a mistake in the legend for Figure 9 as published. The labelling of Figure 9 with macrophages is misleading as we used a RAW264.7 macrophage cell line. The correct legend appears below:

FIGURE 9

AKEX0011 inhibited RAW264.7 from secreting pro-inflammatory cytokines, blocked p38 MAPK signaling, and reduced silica-induced apoptosis and M1 polarization. There were eight cell groups: PBS Control (abbreviated as "Control" in the graphs), PBS + AKEX0011 (200 µg/ml) (abbreviated as "AKEX"), Silica pre, Silica pre + AKEX0011 (100 µg/ml) (abbreviated as "Si pre + AKEX L"), and Silica pre + AKEX0011 (200 µg/ml) (abbreviated as "Si pre + AKEX L"), Silica post,

Silica post + AKEX0011 (100 µg/ml) (abbreviated as "Si post + AKEX L"), and Silica post + AKEX0011 (200 µg/ml) (abbreviated as "Si post + AKEX H"). (**A**–**D**) IL-6 IL-1 β , TNF- α , and TGF- β in cell supernatant detected by ELISA (n = 3). (**E**) Apoptosis (Annexin V+/PI– and Annexin V+/PI+) detection by FACS in each experimental group. (**F**–**H**) WB and quantification of P-p38, p38, P-ASK1, and ASK1. β -actin was used as a loading control. (**I**–**J**) M1 (F4/80 + CD86+) and M2 (F4/80 + CD163+) macrophage proportions detected by FACS in RAW264.7 and statistical analysis (n = 3). (**K**) WB of iNOS P-p65 p65. (**L**, **N**) Quantification of band densities fromWB images in (k), (n = 3). (**M**) mRNA levels of iNOS in lung tissues detected by qPCR (n = 3). All data were presented as mean ± SEM; *p < .05, **p < .01, ***p < .001, and ****p < .0001.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.